In vivo tracking of stem cells for clinical trials in cardiovascular disease

被引：204

作者：

Frangioni, JV

Hajjar, RJ

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Radiol, Div Hematol Oncol, Boston, MA 02215 USA

[2] Beth Israel Deaconess Med Ctr, Mol Imaging Ctr, Boston, MA 02215 USA

[3] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Cardiol Lab Integrat Physiol & Imaging, Boston, MA 02114 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

来源：

CIRCULATION | 2004年 / 110卷 / 21期

关键词：

stem cells; imaging; trials; radiology;

D O I：

10.1161/01.CIR.0000149840.46523.FC

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Various stem cells hold promise for the treatment of human cardiovascular disease. Regardless of stem cell origin, future clinical trials will require that the location and number of such cells be tracked in vivo, over long periods of time. The problem of tracking small numbers of cells in the body is a difficult one, and an optimal solution does not yet exist. We review the many contrast agents and detectors that have been proposed for stem cell tracking during clinical trials, define the characteristics of an ideal imaging technology, and suggest future directions for research.

引用

页码：3378 / 3383

页数：6

共 47 条

[41] In vivo tracking of neural progenitor cell migration to glioblastomas [J].